Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Prescription Drugs & Other Medical Products

Reports

Displaying 11 - 20 of 183. 10 per page. Page 2.

Advanced Search
Report

Impact of Climate Change on Health and Drug Demand

It is anticipated that extreme weather events due to climate change will increase the prevalence of a number of acute and chronic diseases. As a result, the demand for drugs to prevent or treat those conditions is likely to increase.
Report

Drug Development

The cost of bringing a medical product to the U.S. market has been increasing and clinical trials constitute a large portion of these costs. In drug development, the clinical phase lasts an average of around 95 months compared to 31 months for the non-clinical phase and accounts for 69 percent of overall R&D costs (DiMasi, et al., 2016).
ASPE Issue Brief

Opioid Use Treatment of Pregnant/Postpartum Women and their Children

This study represents findings from a descriptive analysis of a linked mother-child Medicaid claims dataset to examine the characteristics of pregnant women who use medication for opioid use disorder (MOUD) or intensive behavioral health treatment; additional analysis describes the mental health and neurodevelopment outcomes of their children at one year and three years.
Research Summary

FDA Breakthrough Therapy Designation Reduced Late-Stage Drug Development Time

This landing page presents the abstract of a paper published in Health Affairs. The full text of the article is available at: https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2023.00837.
ASPE Issue Brief

Medicare Drug Price Negotiation Program: Medicare Prices Negotiated for 2026 Compared to List and U.S. Market Prices

The Inflation Reduction Act (IRA) makes improvements to Medicare to increase accessibility and affordability of prescription drugs for Medicare enrollees, reduce the rate of growth in Medicare drug spending, and improve the financial sustainability of the Medicare program.
ASPE Issue Brief, Database, Dataset, Report

Developing a Database of SUD Treatment Needs

A 2020 study examined the feasibility of using substance use disorder (SUD) patient intake assessment data as source of information for treatment planning.
ASPE Data Point

Linking Medical Product Manufacturing Locations with Natural Hazard Risk: Implications for the Medical Product Supply Chain

This ASPE data point links manufacturer location data with the Federal Emergency Management Agency (FEMA) National Risk Index (NRI), which describes relative risk of experiencing a variety of natural hazards in order to highlight the ways in which natural disasters may pose supply chain vulnerabilities within the U.S.
ASPE Issue Brief

Medical Product Shortages in the United States: Demographic and Geographic Factors and Impacts

Medical product shortages are an ongoing public health concern, with at least 140 products in shortage as of July 2024.We use the Household Pulse Survey to examine how many adults are affected by shortages of critical medical products in the United States.In fall 2023, shortages of medical products impacted about 38.8 million (18 percent) of individuals in the United Stat
ASPE Issue Brief

Impacts of a Nonprofit Membership-Based Pharmaceutical Company on Volume of Drugs Sold and Drug Prices: A Case Study

We report findings of a case study of Civica Rx, a U.S. nonprofit pharmaceutical company whose model is based on long-term hospital membership agreements with minimum volume commitments and buffer stock requirements.Related Products:
Report

The Potential Role of The Nonprofit Pharmaceutical Industry in Addressing Shortages and Increasing Access to Essential Medicines and Low-Cost Medicines

We report findings of a study that described the emerging nonprofit pharmaceutical industry and its commercialization activities to enhance access to affordable and essential drugs, or resiliency in the supply chains of medical products.